Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

9.8101   0.12 (1.24%) 06-06 15:03
Open: 9.64 Pre. Close: 9.69
High: 9.96 Low: 9.49
Volume: 11,258 Market Cap: 41(M)

Technical analysis

as of: 2023-06-06 2:47:44 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 13.39     One year: 15.64
Support: Support1: 9.22    Support2: 7.82
Resistance: Resistance1: 11.47    Resistance2: 13.39
Pivot: 10.15
Moving Average: MA(5): 9.72     MA(20): 10.01
MA(100): 6.61     MA(250): 6.05
MACD: MACD(12,26): 0.2     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 36.4     %D(3): 35.4
RSI: RSI(14): 51.4
52-week: High: 13.17  Low: 2.1
Average Vol(K): 3-Month: 459 (K)  10-Days: 30 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CRBP ] has closed above bottom band by 35.4%. Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10 - 10.05 10.05 - 10.09
Low: 9.45 - 9.51 9.51 - 9.55
Close: 9.61 - 9.69 9.69 - 9.76

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Headline News

Mon, 05 Jun 2023
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Wed, 31 May 2023
Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference - Yahoo Finance

Thu, 25 May 2023
Corbus Pharmaceuticals Holdings Inc. stock falls Thursday, underperforms market - MarketWatch

Tue, 16 May 2023
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Good Buy in the Biotechnology Industry? - InvestorsObserver

Fri, 12 May 2023
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Stock to Watch After Losing -9.04% This Week? - InvestorsObserver

Thu, 11 May 2023
Oppenheimer Upgrades Corbus Pharmaceuticals Holdings (CRBP) - Nasdaq

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 4 (M)
Shares Float 4 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 9.3 (%)
Shares Short 141 (K)
Shares Short P.Month 297 (K)

Stock Financials

EPS -13.4
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.9
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.1
Return on Equity (ttm) -130.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) -3.83
Sales Per Share 0
EBITDA (p.s.) -10.16
Qtrly Earnings Growth 0
Operating Cash Flow -42 (M)
Levered Free Cash Flow -22 (M)

Stock Valuations

PE Ratio -0.74
PEG Ratio 0
Price to Book value 2.51
Price to Sales 0
Price to Cash Flow -0.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.